Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Artery Disease V: Postoperative Nursing Management01:23

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dianionic Tetraalkynylmagnesate Complexes: A Strategy for Propargyl Amine Synthesis.

Organic letters·2026
Same author

Impact of tirzepatide on systemic arterial stiffness assessed by cardio-ankle vascular index in individuals with obesity complicated by type 2 diabetes: A retrospective cohort study in Japan.

Obesity pillars·2026
Same author

Serum Albumin Level Predicts Systemic Arterial Stiffening Mediated Partially by Change in Lean Body Mass: A Retrospective Cohort Study in General Japanese Population.

Vascular health and risk management·2026
Same author

Usefulness of Blood Rheology as a Predictor of Primary Cardiovascular Disease Events in Patients With Stage G3 Chronic Kidney Disease.

Journal of clinical medicine research·2026
Same author

Evaluation of Microcirculation at the Optic Nerve Head in Eyes With Keratoconus.

Investigative ophthalmology & visual science·2026
Same author

Response to "Proximal arterial stiffness, wave reflection, and coronary hemodynamics: a mechanistic perspective on seated innovative cardio-ankle vascular index".

American journal of hypertension·2026

Related Experiment Video

Updated: May 21, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Acute decrease of cardio-ankle vascular index with the administration of beraprost sodium.

Mao Takahashi1, Tomoaki Shiba, Keiichi Hirano

  • 1Department of Internal Medicine, Sakura Hospital, Medical Center, Toho University, Chiba, Japan. takahashi-04@sakura.med.toho-u.ac.jp

Journal of Atherosclerosis and Thrombosis
|June 5, 2012
PubMed
Summary

Beraprost sodium decreased the cardio-ankle vascular index (CAVI) in healthy volunteers, indicating it reflects arterial smooth muscle cell contraction. Brachial-ankle pulse wave velocity (baPWV) did not change.

More Related Videos

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Related Experiment Videos

Last Updated: May 21, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

Area of Science:

  • Cardiovascular Physiology
  • Vascular Biology

Background:

  • Arterial stiffness is a key indicator of cardiovascular health.
  • The cardio-ankle vascular index (CAVI) is a novel measure of arterial stiffness.
  • Prostaglandin I2 analogues like beraprost sodium (BPS) possess vasodilating properties.

Purpose of the Study:

  • To investigate the effects of beraprost sodium (BPS) on the cardio-ankle vascular index (CAVI) in healthy volunteers.
  • To compare the impact of BPS on CAVI versus brachial-ankle pulse wave velocity (baPWV).
  • To elucidate whether CAVI reflects changes in arterial smooth muscle tone.

Main Methods:

  • Eighteen healthy male volunteers received a 40 µg dose of beraprost sodium (BPS).
  • CAVI and baPWV were measured hourly for 4 hours post-administration.
  • Changes in CAVI and baPWV were correlated with changes in systolic and diastolic blood pressure.

Main Results:

  • BPS administration caused minor fluctuations but no significant change in mean blood pressure.
  • CAVI significantly decreased within 1 hour of BPS administration, with the effect persisting for 3 hours.
  • In contrast, baPWV showed no significant changes, and its alterations did not correlate with blood pressure changes, unlike CAVI.

Conclusions:

  • Beraprost sodium effectively reduced CAVI without altering blood pressure in healthy individuals.
  • The observed decrease in CAVI suggests it is sensitive to changes in arterial smooth muscle activity.
  • CAVI may provide insights into vascular smooth muscle tone, differentiating it from baPWV.